Curespec

04/16/2026

Lights, camera… something big is on the way.
A glimpse behind the scenes of what we’ve been working on - stay tuned.

04/14/2026

We’re hiring! 🚀

Curespec is looking for an Applications & Clinical Research Specialist to join our team.

If you're passionate about clinical innovation and want to make a real impact, we’d love to hear from you.

👉 All the details & apply here: https://www.curespec.info/work-with-us

Lowering Blood Pressure Curing the Kidneys ~ Lowering Blood Pressure Curing the Kidneys ~ Join the Curespec Team Curespec is transforming the treatment of chronic kidney disease and hypertension—conditions affecting over 700 million people worldwide.Our proprietary Electro-Hydraulic Acoustic Thera...

03/26/2026

A season of renewal and growth 🌱

Just like in nature, meaningful progress often begins in the smallest places.

Restoring flow, strengthening delicate systems, and building from the ground up - this is where true impact starts.

At Curespec, we believe that innovation lies in understanding and renewing the smallest vessels - because that’s where transformation begins.

It’s not just about advancing technology - it’s about enabling healthier systems and sustainable growth. ✨

03/17/2026

Nephrology is entering a new era of nephroprotection.



In recent years, several therapeutic advances have significantly changed how we approach chronic kidney disease (CKD).

SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists are expanding our ability to slow disease progression and improve outcomes.



Yet one principle remains fundamental:



Blood pressure control is still one of the most powerful tools to protect kidney function.



The challenge is that kidney damage often begins long before clinical symptoms appear.



This is where earlier detection becomes critical.



As nephrology moves toward earlier intervention and precision medicine, advanced diagnostic tools can help clinicians identify kidney injury sooner—supporting earlier treatment decisions and more effective blood pressure management.



Technologies such as Nephrospec aim to support this shift toward proactive nephroprotection.

03/12/2026

We’re excited that Curespec has been selected to attend the 2026 Mayo ClinicMayo Clinic Cardiology & Radiology Innovation Summit in Rochester, Minnesota.

Looking forward to engaging with the Mayo Clinic community and fellow innovators.

03/05/2026

Excited to share that our article has just been published in Frontiers in Medical Technology!

Our study explores the feasibility and safety of electro-hydraulic acoustic therapy (eHAT) as a non-invasive treatment approach for hypertension in patients with chronic kidney disease.
Proud to be part of this collaboration between Shaare Zedek Medical Center Jerusalem and Mayo Cliniclinic, together with an outstanding team of clinicians and researchers.
Looking forward to the next steps in advancing innovative therapies for hypertension.

Full article link in the comments.

02/18/2026

A New Clinical Tool for Hypertension Management.

NEPHROSPEC™ offers physicians a unique way to help patients reduce blood pressure - safely, comfortably, and with no downtime.
A 20-minute session.

Improved renal microcirculation.
Meaningful BP reduction.

This is what next-generation hypertension care looks like.

02/10/2026

Sometimes the biggest clinical achievement isn’t improvement - it’s stopping the decline.

Avigdor, an 80-year-old engineer and lecturer, faced a steady drop in eGFR that led to a pre-dialysis diagnosis.

After starting treatment with Curespec, the downward trend finally shifted - and even moved slightly upward.

His story is about a curve that changed direction.
Here’s the short testimonial video.

02/04/2026

Great news! 🎉
We’ve received official approval from the Hainan regulatory authority - and the Nephrospec device is now authorized for clinical use.
Another meaningful milestone on our mission to bring advanced therapeutic technologies to patients and make a real impact on their lives. Proud of the team and all our partners on this journey!

01/27/2026

✨ U.S. Pilot Clinical Study – 3 of 5 Patients Treated

We’re excited to share major progress in our U.S. pilot study, conducted in collaboration with NephroNet (Atlanta, USA) - a network of more than 400 nephrologists.

Our study is now fully:
✔ IRB-approved
✔ Classified as a Non-Significant Risk (NSR) device
✔ Designed as a 5-patient pilot study
✔ And we’re pleased to report that all 5 patients are enrolled, with 3 already treated.

This marks an important milestone as we continue moving forward with our mission to advance kidney health through innovative non-invasive technology.

Full steam ahead! 🚀

01/22/2026

✨ A meaningful and exciting milestone – our collaborative NephroNet study received official approval in the United States in January 2026!

We are pleased to share that our clinical research, conducted together with NephroNet focused on evaluating electro-hydraulic acoustic therapy to enhance renal blood flow and glomerular filtration in patients with Stage III diabetic nephropathy, received IRB approval in the U.S. in January 2026.

The approval granted by Advarra IRB, allows us to proceed to the next phase of the study following a thorough review of the protocol, informed consent forms, and required modifications. This represents an important step forward for our joint teams and for the patients who may one day benefit from this innovative approach.

We’re proud to continue advancing a novel therapy with the potential to significantly improve outcomes for individuals living with diabetic kidney disease.

A heartfelt thank you to our research team, our partners at NephroNet, collaborators, and everyone who contributed to reaching this milestone.

Now, we move forward — with commitment, optimism, and purpose.